These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37722716)

  • 41. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
    Singh AP; Shah DK
    J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
    Thomas JD; Yurkovetskiy AV; Yin M; Bodyak ND; Gumerov DR; Tang S; Kelleher E; Jones BD; Protopopova M; Qin L; Uttard A; Demady DR; Lowinger TB
    Bioorg Med Chem Lett; 2022 Sep; 72():128876. PubMed ID: 35788036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy.
    Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP
    J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
    Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
    Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).
    Hoffmann RM; Mele S; Cheung A; Larcombe-Young D; Bucaite G; Sachouli E; Zlatareva I; Morad HOJ; Marlow R; McDonnell JM; Figini M; Lacy KE; Tutt AJN; Spicer JF; Thurston DE; Karagiannis SN; Crescioli S
    Sci Rep; 2020 Jun; 10(1):8869. PubMed ID: 32483228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
    Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.
    Lin S; Zhang Y; Yao J; Yang J; Qiu Y; Zhu Z; Hua H
    J Transl Med; 2024 Aug; 22(1):766. PubMed ID: 39143619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
    Clardy SM; Uttard A; Du B; Catcott KC; Lancaster KL; Ditty E; Sadowsky J; Zurita J; Malli N; Qin L; Bradley SP; Avocetien K; Carter T; Kim D; Nazzaro M; Xu L; Pillow TH; Zacharias NT; Lewis GD; Rowntree RK; Iyengar R; Lee DH; Damelin M; Toader D; Lowinger TB
    Mol Cancer Ther; 2024 Jan; 23(1):84-91. PubMed ID: 37774393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment.
    Nagaraja Shastri P; Zhu J; Skidmore L; Liang X; Ji Y; Gu Y; Tian F; Yao S; Xia G
    Mol Cancer Ther; 2020 Sep; 19(9):1822-1832. PubMed ID: 32499302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.
    Juen L; Baltus CB; Gély C; Kervarrec T; Feuillâtre O; Desgranges A; Viaud-Massuard MC; Martin C
    Bioconjug Chem; 2022 Feb; 33(2):418-426. PubMed ID: 35104102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
    Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
    Vasalou C; Proia TA; Kazlauskas L; Przybyla A; Sung M; Mamidi S; Maratea K; Griffin M; Sargeant R; Urosevic J; Rosenbaum AI; Yuan J; Aluri KC; Ramsden D; Hariparsad N; Jones RDO; Mettetal JT
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):994-1005. PubMed ID: 38532525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.